Clinic
Lucile Salter Packard Children's Hospital at Stanford
Lucile Salter Packard Children's Hospital at Stanford was paid $35.67M by Medicaid between Jan 2018 and Dec 2024, across 373 billing codes. Its largest line is 0510, — 7.0% of everything it billed.
33Billing provider infoLUCILE SALTER PACKARD CHILDREN'S HOSPITAL AT STANFORD
PALO ALTO, CA 94304
PALO ALTO, CA 94304
33aNPI1467442749assigned 10/26/2005
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$35.67M
24GClaims707,554
24DCodes billed373
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in California
Rank by total paid#3 of 347
Median peer was paid$191K
This provider vs. median187×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 99,506 | $5.06M | |
| 2019 | 103,654 | $5.39M | |
| 2020 | 80,299 | $4.32M | |
| 2021 | 89,079 | $4.48M | |
| 2022 | 102,450 | $5.07M | |
| 2023 | 117,502 | $5.68M | |
| 2024incomplete | 115,064 | $5.67M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0510 | 7.0% | 58,413 | 52,167 | $2.49M | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 5.5% | 1,787 | 1,755 | $1.96M |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 5.2% | 2,892 | 2,837 | $1.85M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 4.9% | 34,561 | 30,126 | $1.76M |
| 95782 | 3.8% | 1,095 | 1,085 | $1.36M | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.4% | 11,107 | 5,187 | $1.20M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3.2% | 3,517 | 3,403 | $1.15M |
| 0360 | 3.2% | 6,014 | 3,010 | $1.13M | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 3.1% | 2,788 | 2,780 | $1.12M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 3.1% | 11,679 | 11,042 | $1.09M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 2.8% | 228 | 216 | $995K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | 2.6% | 2,705 | 2,596 | $916K |
361 more codes
| S0302 | Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | 2.4% | 11,779 | $865K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.9% | 10,434 | $692K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 1.9% | 9,936 | $678K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 1.5% | 5,015 | $536K |
| 93325 | 1.5% | 4,021 | $519K | |
| 80053 | Comprehensive metabolic panel | 1.3% | 20,146 | $456K |
| 0762 | 1.2% | 6,102 | $416K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 32,482 | $382K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 1.0% | 3,378 | $363K |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | <1% | 155 | $356K |
| 92587 | <1% | 6,406 | $353K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 697 | $327K |
| 93320 | <1% | 2,665 | $296K | |
| 76813 | <1% | 4,042 | $285K | |
| 0710 | <1% | 4,792 | $283K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 8,026 | $269K |
| 59025 | Fetal non-stress test | <1% | 10,657 | $257K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,572 | $245K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,615 | $235K |
| 92550 | <1% | 3,807 | $229K | |
| 92557 | <1% | 3,270 | $219K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,239 | $218K |
| 74183 | <1% | 593 | $215K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 399 | $206K |
| 92567 | <1% | 6,126 | $202K | |
| 97139 | <1% | 9,037 | $188K | |
| 87799 | <1% | 2,662 | $183K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,073 | $175K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,422 | $175K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 913 | $163K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,454 | $162K |
| 72197 | <1% | 510 | $147K | |
| 92522 | <1% | 1,158 | $138K | |
| 86003 | <1% | 1,400 | $137K | |
| J3490 | Unclassified drugs | <1% | 7,493 | $134K |
| 83735 | <1% | 12,313 | $133K | |
| 72141 | <1% | 203 | $131K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 2,261 | $131K |
| 92579 | <1% | 3,226 | $131K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,295 | $125K |
| 97799 | <1% | 4,469 | $118K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,233 | $117K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,856 | $116K |
| J2704 | Injection, propofol, 10 mg | <1% | 9,556 | $116K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,789 | $116K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 7,039 | $114K |
| 93247 | <1% | 721 | $113K | |
| Z7500 | <1% | 3,196 | $109K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 949 | $102K |
| 97803 | <1% | 2,659 | $101K | |
| 82728 | <1% | 5,087 | $95K | |
| 99201 | <1% | 1,415 | $94K | |
| 92523 | <1% | 699 | $92K | |
| 84439 | <1% | 6,512 | $91K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 3,585 | $90K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,181 | $89K |
| 80197 | <1% | 3,302 | $88K | |
| 87497 | <1% | 1,380 | $87K | |
| 72082 | <1% | 1,324 | $82K | |
| 86832 | <1% | 554 | $81K | |
| 92555 | <1% | 4,307 | $81K | |
| 87632 | <1% | 439 | $80K | |
| 76825 | <1% | 370 | $78K | |
| T1024 | Evaluation and treatment by an integrated, specialty team contracted to provide coordinated care to multiple or severely handicapped children, per encounter | <1% | 3,900 | $77K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 1,331 | $76K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,068 | $76K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,369 | $75K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,373 | $74K |
| 76820 | <1% | 1,340 | $74K | |
| 86850 | <1% | 5,722 | $73K | |
| 72146 | <1% | 159 | $72K | |
| 88185 | <1% | 107 | $71K | |
| 76827 | <1% | 453 | $71K | |
| 87150 | <1% | 2,479 | $71K | |
| 84100 | <1% | 9,437 | $68K | |
| 80061 | Lipid panel | <1% | 3,828 | $68K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 2,681 | $64K |
| 95700 | <1% | 195 | $63K | |
| 93356 | <1% | 898 | $61K | |
| 71250 | <1% | 181 | $60K | |
| 97165 | <1% | 1,141 | $58K | |
| 94010 | <1% | 1,928 | $58K | |
| 74230 | <1% | 712 | $57K | |
| V5008 | Hearing screening | <1% | 1,542 | $57K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,400 | $57K |
| Z5924 | <1% | 795 | $55K | |
| 82784 | <1% | 4,536 | $54K | |
| 82248 | <1% | 7,410 | $53K | |
| 97750 | <1% | 1,335 | $52K | |
| 92582 | <1% | 909 | $51K | |
| Z9725 | <1% | 1,181 | $51K | |
| 97802 | <1% | 989 | $50K | |
| 92556 | <1% | 2,025 | $49K | |
| 95819 | <1% | 838 | $48K | |
| 96450 | <1% | 187 | $48K | |
| 81001 | <1% | 7,765 | $46K | |
| 86140 | <1% | 5,739 | $46K | |
| 99070 | <1% | 10,688 | $45K | |
| 87070 | <1% | 2,923 | $45K | |
| 83970 | <1% | 619 | $44K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 6,426 | $44K |
| 83550 | <1% | 4,059 | $43K | |
| Z5916 | <1% | 821 | $42K | |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 6,204 | $42K |
| 96409 | <1% | 1,558 | $41K | |
| 76775 | <1% | 539 | $41K | |
| 86923 | <1% | 243 | $40K | |
| 84403 | <1% | 1,051 | $40K | |
| 92526 | <1% | 782 | $40K | |
| 85027 | <1% | 3,835 | $40K | |
| 86901 | <1% | 6,102 | $40K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,143 | $39K |
| 84460 | <1% | 5,006 | $39K | |
| 95816 | <1% | 434 | $39K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,717 | $38K |
| 90686 | <1% | 1,482 | $37K | |
| X4540 | <1% | 1,110 | $36K | |
| 82977 | <1% | 3,413 | $36K | |
| 83540 | <1% | 4,173 | $36K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,481 | $35K |
| 95812 | <1% | 446 | $35K | |
| 86900 | <1% | 6,114 | $34K | |
| 83516 | <1% | 2,233 | $34K | |
| 93976 | <1% | 158 | $32K | |
| Z5910 | <1% | 691 | $32K | |
| 86480 | <1% | 706 | $32K | |
| 72170 | <1% | 1,046 | $31K | |
| 86833 | <1% | 546 | $31K | |
| 96367 | <1% | 597 | $31K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 765 | $29K |
| 85730 | <1% | 3,006 | $29K | |
| 80076 | <1% | 2,041 | $29K | |
| 84450 | <1% | 3,566 | $29K | |
| 81002 | <1% | 4,886 | $28K | |
| V5010 | Assessment for hearing aid | <1% | 334 | $27K |
| 82570 | <1% | 3,818 | $27K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 357 | $27K |
| 74018 | <1% | 876 | $26K | |
| 82565 | <1% | 2,372 | $26K | |
| 85045 | <1% | 4,318 | $26K | |
| 85610 | <1% | 3,931 | $26K | |
| 80069 | <1% | 1,767 | $25K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,823 | $25K |
| 95811 | <1% | 64 | $23K | |
| 81025 | <1% | 2,574 | $23K | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 1,102 | $23K |
| C9285 | Lidocaine 70 mg/tetracaine 70 mg, per patch | <1% | 631 | $22K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 396 | $22K |
| 82670 | <1% | 547 | $22K | |
| 83002 | <1% | 811 | $21K | |
| 83615 | <1% | 2,517 | $21K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,259 | $20K |
| 0761 | <1% | 185 | $20K | |
| 99367 | <1% | 137 | $20K | |
| 92588 | <1% | 295 | $20K | |
| 82785 | <1% | 785 | $20K | |
| 84550 | <1% | 2,586 | $19K | |
| 83001 | <1% | 690 | $18K | |
| 70543 | <1% | 38 | $18K | |
| 84270 | <1% | 551 | $18K | |
| 0270 | <1% | 1,093 | $17K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 283 | $17K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 186 | $17K |
| Z5918 | <1% | 781 | $17K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 675 | $17K |
| Z5928 | <1% | 350 | $17K | |
| Z5944 | <1% | 201 | $16K | |
| V5264 | Ear mold/insert, not disposable, any type | <1% | 327 | $16K |
| 87340 | <1% | 1,002 | $16K | |
| 85652 | <1% | 4,337 | $16K | |
| 76821 | <1% | 107 | $16K | |
| H1003 | Prenatal care, at-risk enhanced service; education | <1% | 787 | $16K |
| 92611 | <1% | 281 | $15K | |
| 99368 | <1% | 1,626 | $15K | |
| 82247 | <1% | 2,125 | $15K | |
| 99283 | Emergency room visit (moderate) | <1% | 742 | $15K |
| 87077 | <1% | 1,321 | $15K | |
| 85246 | <1% | 518 | $15K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,236 | $15K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,035 | $14K |
| 76536 | <1% | 157 | $14K | |
| 85240 | <1% | 615 | $14K | |
| 86803 | <1% | 622 | $13K | |
| 85245 | <1% | 455 | $13K | |
| 85384 | <1% | 946 | $13K | |
| 81479 | Unlisted molecular pathology procedure | <1% | 68 | $13K |
| 93246 | <1% | 511 | $13K | |
| 92609 | <1% | 162 | $12K | |
| 86360 | <1% | 213 | $12K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,011 | $12K |
| 72081 | <1% | 354 | $12K | |
| 84156 | <1% | 2,828 | $12K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 103 | $12K |
| 87205 | <1% | 1,383 | $11K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,135 | $11K |
| 82610 | <1% | 691 | $11K | |
| 94375 | <1% | 247 | $11K | |
| 99401 | <1% | 689 | $11K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 515 | $11K |
| 86359 | <1% | 228 | $11K | |
| 82962 | <1% | 1,464 | $11K | |
| 92552 | <1% | 480 | $11K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 182 | $10K |
| 83520 | <1% | 486 | $10K | |
| 88230 | <1% | 146 | $10K | |
| A9573 | Injection, gadopiclenol, 1 ml | <1% | 78 | $10K |
| 84305 | <1% | 397 | $10K | |
| 87186 | <1% | 664 | $10K | |
| Z5920 | <1% | 415 | $9K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 964 | $9K |
| 86780 | <1% | 641 | $8K | |
| 82947 | <1% | 1,279 | $8K | |
| 92610 | <1% | 130 | $8K | |
| 83525 | <1% | 474 | $8K | |
| 83993 | <1% | 379 | $8K | |
| 73070 | <1% | 304 | $8K | |
| 90715 | <1% | 138 | $7K | |
| S9446 | Patient education, not otherwise classified, non-physician provider, group, per session | <1% | 469 | $6K |
| 95708 | <1% | 15 | $6K | |
| 96415 | <1% | 103 | $6K | |
| 82550 | <1% | 615 | $6K | |
| 86977 | <1% | 243 | $6K | |
| 95115 | <1% | 715 | $6K | |
| 82139 | <1% | 265 | $6K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 88 | $6K |
| 73100 | <1% | 243 | $6K | |
| 73720 | <1% | 14 | $6K | |
| 88342 | <1% | 137 | $6K | |
| 87210 | <1% | 444 | $6K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 344 | $6K |
| Z5908 | <1% | 106 | $6K | |
| 93243 | <1% | 39 | $5K | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 159 | $5K |
| 92626 | <1% | 85 | $5K | |
| 90678 | <1% | 16 | $5K | |
| 99366 | <1% | 564 | $5K | |
| 84478 | <1% | 516 | $5K | |
| 86355 | <1% | 139 | $5K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 12 | $5K |
| 88184 | <1% | 88 | $5K | |
| 86357 | <1% | 139 | $5K | |
| 84630 | <1% | 332 | $5K | |
| 87507 | <1% | 13 | $5K | |
| 85576 | <1% | 205 | $5K | |
| J9260 | Injection, methotrexate sodium, 50 mg | <1% | 402 | $4K |
| 85651 | <1% | 839 | $4K | |
| 94150 | <1% | 243 | $4K | |
| 71045 | Radiologic examination, chest; single view | <1% | 128 | $4K |
| 70355 | <1% | 79 | $4K | |
| X4500 | <1% | 41 | $4K | |
| Z7514 | <1% | 65 | $4K | |
| 82042 | <1% | 800 | $4K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 68 | $4K |
| 82105 | <1% | 156 | $4K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 52 | $3K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 95 | $3K |
| 83498 | <1% | 76 | $3K | |
| 82330 | <1% | 184 | $3K | |
| 81243 | <1% | 51 | $3K | |
| 83690 | <1% | 317 | $3K | |
| 86160 | <1% | 163 | $3K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 108 | $3K |
| 86706 | <1% | 220 | $3K | |
| 94726 | <1% | 52 | $3K | |
| 94729 | <1% | 55 | $3K | |
| Z5822 | <1% | 119 | $3K | |
| 80195 | <1% | 228 | $3K | |
| 90656 | <1% | 89 | $3K | |
| Z5958 | <1% | 15 | $3K | |
| 93505 | <1% | 26 | $3K | |
| 82465 | <1% | 381 | $3K | |
| 94642 | <1% | 14 | $3K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 39 | $2K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 15 | $2K |
| 73590 | <1% | 82 | $2K | |
| 80180 | <1% | 131 | $2K | |
| 86787 | <1% | 109 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 247 | $2K |
| 73560 | <1% | 79 | $2K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 64 | $2K |
| 88304 | <1% | 91 | $2K | |
| 82627 | <1% | 63 | $2K | |
| 82379 | <1% | 80 | $2K | |
| 84446 | <1% | 89 | $2K | |
| 97003 | <1% | 40 | $2K | |
| 84590 | <1% | 107 | $2K | |
| 74240 | <1% | 24 | $2K | |
| 73090 | <1% | 55 | $1K | |
| 82945 | <1% | 324 | $1K | |
| 82657 | <1% | 38 | $1K | |
| 86255 | <1% | 74 | $1K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 13 | $1K |
| 92570 | <1% | 14 | $1K | |
| 83655 | <1% | 75 | $1K | |
| 86682 | <1% | 53 | $1K | |
| 73620 | <1% | 29 | $1K | |
| 93017 | <1% | 15 | $1K | |
| 88307 | <1% | 27 | $1K | |
| 77073 | <1% | 39 | $957.56 | |
| 76801 | <1% | 12 | $954.90 | |
| 73630 | <1% | 26 | $950.94 | |
| 73610 | <1% | 34 | $948.05 | |
| 0272 | <1% | 13 | $912.90 | |
| 89051 | <1% | 438 | $877.28 | |
| Z4300 | <1% | 12 | $864.00 | |
| 86376 | <1% | 50 | $779.01 | |
| 86225 | <1% | 42 | $778.30 | |
| 83020 | <1% | 37 | $757.17 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 68 | $744.00 |
| 84157 | <1% | 207 | $740.16 | |
| 96411 | <1% | 23 | $709.82 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 45 | $639.01 |
| Z5932 | <1% | 13 | $630.24 | |
| 87102 | <1% | 58 | $611.09 | |
| 77072 | <1% | 13 | $590.28 | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 30 | $583.41 |
| 0636 | <1% | 47 | $554.15 | |
| 82390 | <1% | 38 | $549.26 | |
| 86038 | <1% | 39 | $548.14 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 88 | $534.27 |
| 83721 | <1% | 38 | $527.79 | |
| 96151 | <1% | 39 | $514.20 | |
| 96150 | <1% | 24 | $498.06 | |
| 84480 | <1% | 25 | $476.29 | |
| 86704 | <1% | 31 | $465.95 | |
| Z7610 | <1% | 58 | $423.29 | |
| 82103 | <1% | 42 | $408.05 | |
| 82104 | <1% | 40 | $398.32 | |
| 83090 | <1% | 12 | $358.41 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 46 | $354.54 |
| 97804 | <1% | 14 | $352.77 | |
| 92700 | <1% | 13 | $351.25 | |
| Z6400 | <1% | 17 | $349.80 | |
| 85270 | <1% | 13 | $343.16 | |
| 84425 | <1% | 12 | $342.93 | |
| 82542 | <1% | 14 | $341.35 | |
| 84146 | <1% | 13 | $333.48 | |
| J9100 | Injection, cytarabine, 100 mg | <1% | 37 | $330.57 |
| 99000 | <1% | 73 | $322.80 | |
| 85613 | <1% | 22 | $277.97 | |
| 82607 | <1% | 13 | $268.44 | |
| 82525 | <1% | 12 | $259.27 | |
| 43762 | <1% | 14 | $258.30 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 48 | $252.44 |
| 86762 | <1% | 12 | $247.51 | |
| 90685 | <1% | 12 | $244.72 | |
| 80164 | <1% | 12 | $225.15 | |
| 86800 | <1% | 12 | $216.55 | |
| 86708 | <1% | 14 | $210.79 | |
| 86592 | <1% | 41 | $205.45 | |
| 82746 | <1% | 12 | $188.83 | |
| 86141 | <1% | 12 | $148.49 | |
| 84520 | <1% | 32 | $144.83 | |
| 84295 | <1% | 28 | $122.89 | |
| 86880 | <1% | 17 | $120.17 | |
| 82085 | <1% | 13 | $117.00 | |
| Z4311 | <1% | 12 | $98.43 | |
| 82310 | <1% | 13 | $83.69 | |
| 89220 | <1% | 14 | $40.79 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 17 | $2.67 |
| S9470 | Nutritional counseling, dietitian visit | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCARMACK, TIMOTHY (CHIEF FINANCIAL OFFICER)